{"hands_on_practices": [{"introduction": "The first step in mastering statistical inference is to correctly translate a real-world question into a precise mathematical framework. This practice provides a classic scenario—an A/B test—to build your foundational skills in formulating null and alternative hypotheses. Here, we move beyond abstract theory to a concrete example involving proportions, forcing us to distinguish between the 'skeptical' default position (the null hypothesis, $H_0$) and the specific research claim we seek to prove (the alternative hypothesis, $H_a$). Properly setting up these hypotheses is the most critical step in ensuring your statistical test answers the right question. [@problem_id:1940648]", "problem": "A digital marketing team at an e-commerce company is conducting an A/B test to evaluate a new email campaign strategy. They split a large list of subscribers into two random groups. Group A receives an email with a generic subject line, while Group B receives an email with a personalized subject line that includes the recipient's first name. The team wants to determine if the personalization strategy leads to a statistically significant *increase* in the email open rate.\n\nLet $p_{generic}$ represent the true population proportion of subscribers who open an email with a generic subject line.\nLet $p_{personalized}$ represent the true population proportion of subscribers who open an email with a personalized subject line.\n\nThe team's research question is: \"Does a personalized subject line improve the email open rate?\"\n\nWhich of the following represents the correct null hypothesis ($H_0$) and alternative hypothesis ($H_a$) for testing this specific research question?\n\nA. $H_0: p_{personalized} = p_{generic}$ vs. $H_a: p_{personalized} \\ne p_{generic}$\n\nB. $H_0: p_{personalized} > p_{generic}$ vs. $H_a: p_{personalized} = p_{generic}$\n\nC. $H_0: p_{personalized} = p_{generic}$ vs. $H_a: p_{personalized} < p_{generic}$\n\nD. $H_0: p_{personalized} = p_{generic}$ vs. $H_a: p_{personalized} > p_{generic}$\n\nE. Let $\\hat{p}_{generic}$ and $\\hat{p}_{personalized}$ be the sample proportions from the experiment. Then, $H_0: \\hat{p}_{personalized} = \\hat{p}_{generic}$ vs. $H_a: \\hat{p}_{personalized} > \\hat{p}_{generic}$.", "solution": "The goal of hypothesis testing is to use sample data to make an inference about a population. The process begins by formulating two competing hypotheses: the null hypothesis ($H_0$) and the alternative hypothesis ($H_a$).\n\n**Step 1: Formulating the Null Hypothesis ($H_0$)**\n\nThe null hypothesis, $H_0$, represents the default assumption or the statement of \"no effect.\" It is the hypothesis that we will assume to be true unless we gather sufficient evidence against it. In this scenario, the \"no effect\" position is that the personalization of the subject line makes no difference to the email open rate. This means the true population proportions for both types of emails are equal.\n\nMathematically, this is expressed as:\n$$H_0: p_{personalized} = p_{generic}$$\n\nThis can also be written in terms of the difference between the proportions:\n$$H_0: p_{personalized} - p_{generic} = 0$$\nThe null hypothesis always contains a statement of equality (e.g., $=$, $\\le$, or $\\ge$). The standard convention for a two-sided or one-sided test is to use a strict equality in the null hypothesis.\n\n**Step 2: Formulating the Alternative Hypothesis ($H_a$)**\n\nThe alternative hypothesis, $H_a$, is the research claim we are trying to find evidence *for*. It is what we would conclude if we reject the null hypothesis. The problem states that the marketing team wants to determine if the personalization strategy leads to an *increase* in the email open rate. This translates to the claim that the true proportion of opens for personalized emails is *greater than* the true proportion for generic emails.\n\nMathematically, this is expressed as a strict inequality:\n$$H_a: p_{personalized} > p_{generic}$$\n\nThis can also be written as:\n$$H_a: p_{personalized} - p_{generic} > 0$$\nThis formulation makes it a one-tailed (specifically, a right-tailed) test, as we are only interested in detecting a difference in one specific direction (an increase).\n\n**Step 3: Analyzing the Options**\n\nLet's evaluate the given choices based on our derived hypotheses:\n\n- **A. $H_0: p_{personalized} = p_{generic}$ vs. $H_a: p_{personalized} \\ne p_{generic}$**: This represents a two-tailed test. It would be used to test if there is *any* difference (either an increase or a decrease) in the open rate. This is not what the team wants to test; they are specifically interested in an *increase*.\n\n- **B. $H_0: p_{personalized} > p_{generic}$ vs. $H_a: p_{personalized} = p_{generic}$**: This incorrectly swaps the roles of the null and alternative hypotheses. The null hypothesis should contain the statement of equality.\n\n- **C. $H_0: p_{personalized} = p_{generic}$ vs. $H_a: p_{personalized} < p_{generic}$**: This represents a left-tailed test. It would be used to test if personalization *decreases* the open rate, which is the opposite of the research question.\n\n- **D. $H_0: p_{personalized} = p_{generic}$ vs. $H_a: p_{personalized} > p_{generic}$**: This correctly sets up the null hypothesis as a statement of no difference and the alternative hypothesis as the specific claim of an increase in the open rate due to personalization. This perfectly matches the research question.\n\n- **E. $H_0: \\hat{p}_{personalized} = \\hat{p}_{generic}$ vs. $H_a: \\hat{p}_{personalized} > \\hat{p}_{generic}$**: This option is incorrect because hypotheses are always statements about population parameters (in this case, $p_{personalized}$ and $p_{generic}$), which are unknown true values. Hypotheses are never about sample statistics (in this case, $\\hat{p}_{personalized}$ and $\\hat{p}_{generic}$), which are calculated from the collected data. We use sample statistics to test claims about population parameters.\n\nTherefore, the correct formulation of the null and alternative hypotheses is given in option D.", "answer": "$$\\boxed{D}$$", "id": "1940648"}, {"introduction": "Building on the fundamentals, this exercise places you in the role of a computational biologist making a critical 'go/no-go' decision in drug development. The choice between a one-sided and two-sided test is not merely academic; it has profound practical implications and directly reflects the scientific objective. This problem will challenge you to justify a one-sided hypothesis test based on a pre-defined criterion for a drug's efficacy—in this case, the specific goal of *reducing* an oncogene's expression. This practice illustrates how hypothesis formulation guides real-world scientific and financial decisions in biotechnology. [@problem_id:2410281]", "problem": "A biotechnology company is evaluating a small molecule that targets a transcription factor known to activate an oncogene. In an in vitro experiment with human cancer cell lines, you perform ribonucleic acid sequencing (RNA-seq), normalize counts, and analyze log-base-two expression. Let $n_{\\mathrm{t}}$ and $n_{\\mathrm{c}}$ denote the numbers of independent biological replicates under treatment and control, respectively, with $n_{\\mathrm{t}} = 6$ and $n_{\\mathrm{c}} = 6$. Let $\\mu_{\\mathrm{t}}$ and $\\mu_{\\mathrm{c}}$ denote the population means of log-base-two expression for the oncogene under treatment and control, respectively, and let $\\Delta = \\mu_{\\mathrm{t}} - \\mu_{\\mathrm{c}}$ denote the population mean difference. After appropriate normalization and variance stabilization, you plan to conduct a parametric test on $\\Delta$ at significance level $\\alpha = 0.05$.\n\nThe company’s pre-registered primary decision rule for the go/no-go decision is: proceed to animal studies only if there is statistically significant evidence that the oncogene’s mean expression is lower under treatment than under control. If expression is higher under treatment, this will be investigated in a separate safety analysis but will not count toward the primary endpoint or alter the go/no-go rule for efficacy. You will not reinterpret an unexpected increase in expression as “success.”\n\nFrom first principles of hypothesis testing in computational biology and bioinformatics, where the null hypothesis represents no efficacy-relevant effect and the alternative represents the effect of interest, which option correctly specifies whether the primary alternative hypothesis should be one-sided or two-sided for the oncogene’s expression, and correctly states both the one-sided and two-sided null/alternative hypothesis pairs in terms of $\\Delta$?\n\nA. Use a one-sided alternative focused on downregulation for the primary test because only a decrease in expression is efficacy-relevant under the pre-registered decision rule. One-sided: $H_{0}\\!:\\,\\Delta \\ge 0$ versus $H_{a}\\!:\\,\\Delta < 0$. Two-sided (for comparison): $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n\nB. Use a two-sided alternative for the primary test because two-sided tests maximize power at fixed $\\alpha$. One-sided (for comparison): $H_{0}\\!:\\,\\Delta \\ge 0$ versus $H_{a}\\!:\\,\\Delta < 0$. Two-sided: $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n\nC. Use a one-sided alternative for the primary test because the drug is expected to inhibit. One-sided: $H_{0}\\!:\\,\\Delta \\le 0$ versus $H_{a}\\!:\\,\\Delta > 0$. Two-sided: $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n\nD. Use a two-sided alternative for the primary test because there are many genes in RNA-seq and multiple-testing corrections require two-sided tests. One-sided (for comparison): $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta < 0$. Two-sided: $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.", "solution": "The problem statement must first be validated for scientific and logical integrity.\n\nStep 1: Extract Givens\n- Experiment: Evaluation of a small molecule targeting a transcription factor for an oncogene in human cancer cell lines.\n- Measurement: Ribonucleic acid sequencing (RNA-seq), log-base-two expression.\n- Sample sizes: $n_{\\mathrm{t}} = 6$ (treatment replicates), $n_{\\mathrm{c}} = 6$ (control replicates).\n- Population parameters: $\\mu_{\\mathrm{t}}$ is the population mean log-expression under treatment; $\\mu_{\\mathrm{c}}$ is the population mean log-expression under control.\n- Parameter of interest: $\\Delta = \\mu_{\\mathrm{t}} - \\mu_{\\mathrm{c}}$, the population mean difference in log-expression.\n- Statistical framework: A parametric test on $\\Delta$ at significance level $\\alpha = 0.05$.\n- Primary decision rule: \"proceed to animal studies only if there is statistically significant evidence that the oncogene’s mean expression is lower under treatment than under control.\"\n- Principle of hypothesis formulation: \"the null hypothesis represents no efficacy-relevant effect and the alternative represents the effect of interest.\"\n\nStep 2: Validate Using Extracted Givens\nThe problem describes a standard scenario in preclinical drug discovery and bioinformatics.\n- **Scientifically Grounded:** The setup is a canonical example of differential gene expression analysis using RNA-seq data. The use of log-transformed expression values, hypothesis testing, and the distinction between one-sided and two-sided tests are all fundamental concepts in biostatistics. The problem is scientifically sound.\n- **Well-Posed:** The problem provides a clear decision rule and asks for the correct statistical hypothesis formulation that aligns with this rule. A unique, correct formulation can be derived from these premises. The problem is well-posed.\n- **Objective:** The problem is stated using precise, objective language. The decision criterion is unambiguous. The problem is objective.\n- **Completeness and Consistency:** All necessary information to formulate the hypotheses is provided. There are no internal contradictions.\n\nStep 3: Verdict and Action\nThe problem is valid. I will proceed with a full derivation and evaluation.\n\nThe fundamental principle of hypothesis testing is to formulate hypotheses before observing the data, based on the scientific question and the decisions that will be made as a result of the test. The problem explicitly states that \"the null hypothesis represents no efficacy-relevant effect and the alternative represents the effect of interest.\"\n\nThe \"effect of interest,\" which would trigger a \"go\" decision, is defined by the primary decision rule: \"statistically significant evidence that the oncogene’s mean expression is lower under treatment than under control.\" Mathematically, this translates to $\\mu_{\\mathrm{t}} < \\mu_{\\mathrm{c}}$. Expressed in terms of the parameter of interest, $\\Delta = \\mu_{\\mathrm{t}} - \\mu_{\\mathrm{c}}$, this is equivalent to $\\Delta < 0$. Therefore, the alternative hypothesis, $H_a$, which represents the effect of interest, must be:\n$$H_a: \\Delta < 0$$\n\nThe null hypothesis, $H_0$, represents the absence of the effect of interest. It is the logical complement of the alternative hypothesis. If the alternative is $\\Delta < 0$, then the null hypothesis must cover all other possibilities, namely that the treatment either has no effect or increases the expression of the oncogene. This is stated as \"no efficacy-relevant effect.\" An increase in expression is explicitly not considered efficacious. Thus, the null hypothesis is $\\Delta \\ge 0$.\nThe correct hypothesis pair for the primary test is therefore:\n$$H_0: \\Delta \\ge 0 \\quad \\text{versus} \\quad H_a: \\Delta < 0$$\nThis is a one-sided (or one-tailed) test. A one-sided test is required because the decision rule is directional. The company is only interested in detecting a decrease in expression as evidence of efficacy. An increase in expression ($\\Delta > 0$) leads to the same \"no-go\" decision (for efficacy) as no change in expression ($\\Delta = 0$).\n\nFor completeness, a two-sided test would be appropriate if the question were whether the treatment has *any* effect, either increasing or decreasing expression. In that case, the hypotheses would be:\n$$H_0: \\Delta = 0 \\quad \\text{versus} \\quad H_a: \\Delta \\ne 0$$\nThis structure tests for any non-zero difference and is not aligned with the specified directional decision rule for efficacy.\n\nNow, I will evaluate each option.\n\nA. Use a one-sided alternative focused on downregulation for the primary test because only a decrease in expression is efficacy-relevant under the pre-registered decision rule. One-sided: $H_{0}\\!:\\,\\Delta \\ge 0$ versus $H_{a}\\!:\\,\\Delta < 0$. Two-sided (for comparison): $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n- The choice of a one-sided test is correct.\n- The justification, based on the pre-registered decision rule and the definition of efficacy-relevant effect, is correct and rigorous.\n- The formulation of the one-sided hypothesis pair, $H_{0}\\!:\\,\\Delta \\ge 0$ versus $H_{a}\\!:\\,\\Delta < 0$, is correct.\n- The formulation of the two-sided hypothesis pair for comparison is also the standard, correct form.\nThis option is entirely correct.\n\nB. Use a two-sided alternative for the primary test because two-sided tests maximize power at fixed $\\alpha$. One-sided (for comparison): $H_{0}\\!:\\,\\Delta \\ge 0$ versus $H_{a}\\!:\\,\\Delta < 0$. Two-sided: $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n- The choice of a two-sided test is incorrect, as the decision rule is directional.\n- The justification that \"two-sided tests maximize power at fixed $\\alpha$\" is a false statement. For a given $\\alpha$, a one-sided test has greater statistical power to detect an effect in the specified direction than a two-sided test. A two-sided test splits the rejection region into two tails, thus requiring a larger effect size to achieve significance in any one direction.\nThis option is incorrect.\n\nC. Use a one-sided alternative for the primary test because the drug is expected to inhibit. One-sided: $H_{0}\\!:\\,\\Delta \\le 0$ versus $H_{a}\\!:\\,\\Delta > 0$. Two-sided: $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n- The choice of a one-sided test is correct, but the reason provided (\"because the drug is expected to inhibit\") is weaker than using the pre-specified decision rule. Hypotheses should be based on the question being asked, not on prior beliefs.\n- The formulation of the one-sided hypothesis, $H_{a}\\!:\\,\\Delta > 0$, is incorrect. This would test for a significant *increase* in oncogene expression, which contradicts the stated goal of the study. The company is looking for a *decrease*.\nThis option is incorrect.\n\nD. Use a two-sided alternative for the primary test because there are many genes in RNA-seq and multiple-testing corrections require two-sided tests. One-sided (for comparison): $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta < 0$. Two-sided: $H_{0}\\!:\\,\\Delta = 0$ versus $H_{a}\\!:\\,\\Delta \\ne 0$.\n- The choice of a two-sided test is incorrect for the same reason as in B.\n- The justification that \"multiple-testing corrections require two-sided tests\" is false. Standard procedures for controlling the false discovery rate or family-wise error rate (e.g., Benjamini-Hochberg, Bonferroni) operate on p-values, regardless of whether they originate from one-sided or two-sided tests. Furthermore, the problem concerns the primary hypothesis for a single pre-specified oncogene, not a genome-wide screen, so multiple testing is not the central issue defining the hypothesis structure for this gene.\n- The formulation of the one-sided null hypothesis as $H_0: \\Delta = 0$ is a common simplification, but the composite null $H_0: \\Delta \\ge 0$ (as in option A) is more technically complete as it is the exact complement of the alternative $H_a: \\Delta < 0$. While the test procedure is often identical, the formulation in A is more rigorous.\nThis option is incorrect.\n\nBased on this analysis, Option A is the only one that correctly identifies the test type, provides the correct justification based on the stated decision rule, and formulates both the one-sided and two-sided hypotheses correctly.\n\nFinal Verdict: Option A is correct.", "answer": "$$\\boxed{A}$$", "id": "2410281"}, {"introduction": "Is every statistically significant result biologically meaningful? This advanced practice challenges the standard 'point null' hypothesis (e.g., $H_0: \\theta = 0$) and introduces a more nuanced and powerful concept: the interval null hypothesis. In many bioinformatics applications, especially differential gene expression analysis, we are only interested in changes that exceed a certain magnitude. This exercise teaches you how to formally define 'no biologically meaningful effect' as an interval, such as a log-fold change $\\theta$ within $[-0.5, 0.5]$, and test for effects that are large enough to be considered important. Mastering this concept allows you to align your statistical analysis more closely with biological reality, focusing on discovering substantial effects rather than any non-zero change. [@problem_id:2410261]", "problem": "You are analyzing differential gene expression between two experimental conditions using RNA sequencing (RNA-seq). For a given gene, let the true log base 2 fold change be denoted by $\\theta$, where $\\theta = \\log_2(\\mu_1 / \\mu_2)$ and $\\mu_1$ and $\\mu_2$ are the true mean expression levels under conditions $1$ and $2$, respectively. In this study, you adopt a definition of “no biologically meaningful effect” that corresponds to $\\theta$ lying within the closed interval $[-0.5, 0.5]$. You plan to conduct a hypothesis test aligned with this definition of “no effect.”\n\nWhich pair of null and alternative hypotheses correctly encodes this decision rule, using the definition of “no effect” as being within $[-0.5, 0.5]$?\n\nA. $H_0\\!: \\theta \\in [-0.5, 0.5]$ versus $H_a\\!: \\theta < -0.5 \\ \\text{ or }\\ \\theta > 0.5$.\n\nB. $H_0\\!: \\theta = 0$ versus $H_a\\!: \\theta \\neq 0$.\n\nC. $H_0\\!: |\\theta| \\ge 0.5$ versus $H_a\\!: |\\theta| < 0.5$.\n\nD. $H_0\\!: \\theta \\le -0.5 \\ \\text{ or }\\ \\theta \\ge 0.5$ versus $H_a\\!: -0.5 < \\theta < 0.5$.\n\nE. $H_0\\!: -0.5 < \\theta < 0.5$ versus $H_a\\!: \\theta \\le -0.5 \\ \\text{ or }\\ \\theta \\ge 0.5$.", "solution": "The problem statement is subjected to validation.\n\n### Step 1: Extract Givens\n- The parameter of interest is the true log base $2$ fold change, denoted by $\\theta$.\n- The definition of this parameter is $\\theta = \\log_2(\\mu_1 / \\mu_2)$, where $\\mu_1$ and $\\mu_2$ are the true mean expression levels for two experimental conditions.\n- The definition of “no biologically meaningful effect” is that $\\theta$ lies within the closed interval $[-0.5, 0.5]$.\n- The task is to identify the correct pair of null and alternative hypotheses that aligns with this definition for the purpose of analyzing differential gene expression.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded:** The problem is set in the context of RNA-seq data analysis, a standard technique in computational biology. The use of log-fold change is a fundamental metric for quantifying differential expression. The concept of defining a region of practical equivalence or biological non-significance (here, $[-0.5, 0.5]$) and testing against it is a statistically sound and commonly used practice, often referred to as testing with an interval null hypothesis or a \"minimal effect\" test. This is more rigorous than a simple point-null test. The problem is scientifically grounded.\n- **Well-Posed:** The problem is clearly defined. It provides a precise mathematical definition for \"no biologically meaningful effect\" and asks for the corresponding formal hypothesis test structure. The question is unambiguous and has a single correct interpretation within the standard framework of frequentist hypothesis testing.\n- **Objective:** The language is formal and objective. The term \"biologically meaningful effect\" is given a precise, quantitative definition, removing any subjectivity.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will be derived.\n\n### Derivation\nIn the framework of hypothesis testing, the null hypothesis, $H_0$, represents the default state, the status quo, or a statement of \"no effect.\" The alternative hypothesis, $H_a$, represents the state for which we seek to find evidence; it is the \"discovery\" or the \"effect\" we wish to prove. The burden of proof lies in rejecting the null hypothesis in favor of the alternative.\n\nThe problem context is \"analyzing differential gene expression.\" The purpose of such an analysis is to identify genes that are, in fact, differentially expressed in a biologically meaningful way. Therefore, the \"discovery\" is that a gene exhibits a meaningful change. This statement of a meaningful effect must be the alternative hypothesis, $H_a$.\n\nThe problem defines \"no biologically meaningful effect\" as the case where the true log-fold change $\\theta$ lies within the closed interval $[-0.5, 0.5]$. This is the state of \"no discovery.\" Consequently, this statement must be the null hypothesis, $H_0$.\n\nBased on this logic:\n- The null hypothesis is $H_0\\!: \\theta \\in [-0.5, 0.5]$. This can also be written as $H_0\\!: -0.5 \\le \\theta \\le 0.5$.\n\n- The alternative hypothesis, $H_a$, is the logical complement of the null hypothesis. It represents a biologically meaningful effect. If $\\theta$ is not in the interval $[-0.5, 0.5]$, then it must be either less than $-0.5$ or greater than $0.5$.\n- The alternative hypothesis is $H_a\\!: \\theta \\notin [-0.5, 0.5]$, which is written as $H_a\\!: \\theta < -0.5 \\ \\text{or}\\ \\theta > 0.5$.\n\nThis structure is a test against an interval null. We reject $H_0$ only if there is sufficient evidence that the true effect $\\theta$ is large in magnitude (either a large downregulation, $\\theta < -0.5$, or a large upregulation, $\\theta > 0.5$).\n\n### Option-by-Option Analysis\n\n**A. $H_0\\!: \\theta \\in [-0.5, 0.5]$ versus $H_a\\!: \\theta < -0.5 \\ \\text{ or }\\ \\theta > 0.5$.**\nThis formulation places the interval of \"no biologically meaningful effect\" as the null hypothesis, $H_0$. The alternative hypothesis, $H_a$, represents the condition of a biologically meaningful effect. This structure correctly places the burden of proof on demonstrating a significant change, which is the standard goal of differential expression analysis. This matches our derivation precisely.\nVerdict: **Correct**.\n\n**B. $H_0\\!: \\theta = 0$ versus $H_a\\!: \\theta \\neq 0$.**\nThis is a point-null hypothesis test. It tests for *any* deviation from zero, no matter how small. The problem explicitly defines \"no biologically meaningful effect\" as an interval, $[-0.5, 0.5]$, not just the single point $\\theta=0$. Under this test, an observed effect corresponding to a true $\\theta = 0.1$ could be statistically significant, leading to rejection of $H_0$, but this effect is defined as *not* biologically meaningful by the problem statement. This test formulation does not respect the provided definition of a meaningful effect.\nVerdict: **Incorrect**.\n\n**C. $H_0\\!: |\\theta| \\ge 0.5$ versus $H_a\\!: |\\theta| < 0.5$.**\nThis formulation posits that a meaningful effect ($|\\theta| \\ge 0.5$) is the null hypothesis and that no meaningful effect ($|\\theta| < 0.5$) is the alternative. This structure corresponds to a test of equivalence, where the goal is to prove that the effect is small (i.e., that the conditions are equivalent). While a valid form of hypothesis test, it does not match the typical goal of \"analyzing differential gene expression,\" which is to find genes that *are* different. The burden of proof is reversed. Moreover, the problem defines the \"no effect\" interval as closed, $[-0.5, 0.5]$. The alternative hypothesis here, $H_a\\!: |\\theta| < 0.5$, is equivalent to $-0.5 < \\theta < 0.5$, which is an open interval and thus inconsistent with the definition provided.\nVerdict: **Incorrect**.\n\n**D. $H_0\\!: \\theta \\le -0.5 \\ \\text{ or }\\ \\theta \\ge 0.5$ versus $H_a\\!: -0.5 < \\theta < 0.5$.**\nThis is identical in substance to option C. It is a test for equivalence, where the null hypothesis is that a meaningful effect exists, and the alternative is that the effect lies within the \"no effect\" zone. As explained for option C, this inverts the standard goal of a differential expression analysis, which seeks to discover large effects, not prove their absence.\nVerdict: **Incorrect**.\n\n**E. $H_0\\!: -0.5 < \\theta < 0.5$ versus $H_a\\!: \\theta \\le -0.5 \\ \\text{ or }\\ \\theta \\ge 0.5$.**\nThis formulation is similar to option A, which is correct in principle. However, it fails on a technical detail. The problem states that \"no biologically meaningful effect\" corresponds to $\\theta$ lying within the **closed interval** $[-0.5, 0.5]$. This option defines the null hypothesis as an open interval, $H_0\\!: -0.5 < \\theta < 0.5$. This contradicts the explicit problem definition. The endpoints $\\theta = -0.5$ and $\\theta = 0.5$ are part of the \"no effect\" region and must be included in the null hypothesis.\nVerdict: **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "2410261"}]}